Table 1.
Study and Treatment Characteristics of 90 Eligible Trials Included in Analysis
| Variables | All Studies (n = 90) |
|---|---|
| Total number of patients | |
| Accrued | 4464 |
| Treated | 4125 |
| Completed | 3787 |
| Age, y | |
| Mean (SD) | 50.6 (4.9) |
| Median (IQR) | 50.6 (48–53) |
| Missing, n (%) | 12 (13.3) |
| Study type, n (%) | |
| Retrospective | 22 (24.4) |
| Prospective | 68 (75.6) |
| Multicenter | 41 (45.6) |
| Single-center | 49 (54.4) |
| Treatment type, n (%) | |
| Lanreotide | 33 (36.7) |
| Octreotide | 53 (58.9) |
| Other (ie, both) | 4 (4.4) |
| Treatment arms, n (%) | |
| Lanreotide ATG | 16 (48.5) |
| Lanreotide SR | 17 (51.5) |
| Octreotide LAR | 34 (64.2) |
| Octreotide SC | 19 (35.9) |
| Treatment duration, mo | |
| Mean (SD) | 15.1 (12.6) |
| Median (IQR) | 12 (6–18) |
| Dosing scheme, n (%) | |
| Titrated | 51 (56.7) |
| Fixed | 12 (13.3) |
| Fixed/titrated | 27 (30) |
| Year of study, n (%) | |
| 1987–1989 | 4 (3.9) |
| 1990–1999 | 30 (29.1) |
| 2000–2009 | 56 (53.4) |
| 2010–2012 | 13 (12.6) |
| Treatment-naïve patients, % | |
| Mean (SD) | 38 (39) |
| Median (IQR) | 24 (0–70) |
| SRL-naïve patients, % | |
| Mean (SD) | 58 (43) |
| Median (IQR) | 68 (8–100) |
| Prior surgery, % | |
| Mean (SD) | 45 (32) |
| Median (IQR) | 52 (0–63) |
| Prior radiotherapy, % | |
| Mean (SD) | 20 (20) |
| Median (IQR) | 18 (0–33) |
| Short octreotide test, n (%) | |
| Yes | 26 (29) |
| No | 64 (71) |
| Switch study, n (%) | |
| Yes | 13 (14) |
| No | 76 (84) |
| Undetermined | 1 (1) |
| Prior SRL therapy, n (%) | |
| Yes | 54 (60) |
| No | 33 (37) |
| Undetermined | 3 (3) |
| Preselection favorable, n (%) | |
| Yes | 29 (32) |
| No | 59 (66) |
| Undetermined | 2 (2) |
Abbreviation: IQR, interquartile range.